CONTEPO

Launch

fosfomycin disodium

NDAINTRAVENOUSPOWDERPriority Review
Approved
Oct 2025
Lifecycle
Launch
Competitive Pressure
0/100

Mechanism of Action

[ see Microbiology () ] .

Indications (4)

older with complicated urinary tract infections (cUTI)including acute pyelonephritiscaused by susceptible isolates of Escherichia coliKlebsiella pneumoniae

Loss of Exclusivity

LOE Date
Jan 30, 2039
157 months away
Patent Expiry
Jan 30, 2039
Exclusivity Expiry
Oct 22, 2033

Patent Records (3)

Patent #ExpiryTypeUse Code
10086006
Oct 12, 2034
U-4332
9345717
Oct 27, 2034
U-4332
11541064
Jan 30, 2039
U-4331
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers